Verve Therapeutics, Inc. (VERV)

Market Cap	419.83M
Revenue (ttm)	16.05M
Net Income (ttm)	-196.83M
Shares Out	83.97M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,188,214
Open	4.95
Previous Close	4.98
Day's Range	4.80 - 5.09
52-Week Range	4.59 - 21.04
Beta	1.86
Analysts	Buy
Price Target	33.00 (+560.0%)
Earnings Date	Aug 8, 2024

About VERV

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 255
• Stock Exchange: NASDAQ
• Ticker Symbol: VERV

Financial Performance

In 2023, VERV's revenue was $11.76 million, an increase of 505.77% compared to the previous year's $1.94 million. Losses were -$200.07 million, 27.1% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for VERV stock is "Buy." The 12-month stock price forecast is $33.0, which is an increase of 560.00% from the latest price.

Price Target

$33.0

(560.00% upside)

Analyst Consensus: Buy